Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged over 18 years old;~* Who received in the last 7 days the diagnosis of metastatic incurable bladder, prostate, kidney, colorectal or sarcoma cancer (including recurrence) during the announcement visit;~* Whose life expectancy is estimated ≥ 6 months by their treating oncologist;~* Who have a WHO performance score \< 3 (to be coherent with the life expectancy);~* Who have an albumin level \> 30g/liter (patients with an acceptable state of nutrition);~* Who gave their signed consent to participate in the study;~* Who are covered by a social insurance.~Exclusion Criteria:~* Patients diagnosed with cerebral metastases;~* Patients with locally advanced cancer without metastases;~* Patients with an advanced or metastatic cancer amenable to curative intent treatment;~* Patients suffering from a psychological vulnerability that might alter their reasoning or judgment capacities;~* Patients with a psychological or physical incapacity to answer the questionnaires, attested by the medical staff;~* Patients under custodial sentence or under tutelage or protection of vulnerable adults

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
- Control Arm (Type: OTHER): Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.

Based on this trial design, predict the completion outcome and termination type (if applicable).